Prior authorization not specified

The policy excerpt does not state routine prior authorization requirements for the STI tests listed; follow payer-specific administrative rules and member benefit coverage for any authorization needs.

• If local payer or government (Medicare/Medicaid) policies require prior authorization, those rules apply.
• No standalone prior‑auth language for listed CPT/HCPCS codes is present in the policy excerpt; verify in the payer portal before billing.

Prior authorization — none specified in excerpt

No explicit prior authorization conditions are described in the document excerpts; when ordering FDA‑approved assays, document clinical indication and specimen type and follow Blue Cross Blue Shield of Louisiana administrative rules.

• Providers should check member benefits and payer portals for any local prior‑auth requirements.
• Document clinical indication and specimen to support medical necessity if requested.

Rapid/near-patient NAAT use

Near‑patient/rapid molecular NAATs (e.g., Cepheid GeneXpert Xpert CT/NG) offer high sensitivity and rapid turnaround and can influence same‑day treatment decisions; document clinical indication and use of the rapid NAAT when performed.

• Use validated near‑patient NAAT platforms as appropriate (e.g., GeneXpert) and record the assay name and result timing.
• Document that rapid testing informed same‑day management when used to guide treatment.

Prior authorization — none specified

The policy fragment contains no explicit prior authorization statements for listed CPT/HCPCS codes; providers must verify payer and government policy requirements prior to submission.

• Confirm prior‑auth needs for individual member plans and for any codes added via off‑cycle coding.
• Codes listed in this policy are for reference and may not reflect payer billing rules.

Prior authorization not specified in guideline excerpts

Guideline excerpts and the policy do not include routine prior authorization triggers for STI testing; always follow applicable payer and government policies when ordering.

• If conflict exists between this policy and LCD/NCD/state Medicaid, government policy prevails and may impose authorization requirements.
• Check the Medicare and state Medicaid coverage databases when treating beneficiaries.

Prior authorization for listed codes

No explicit prior authorization requirements are stated for the CPT/HCPCS codes listed in the policy fragment; verify payer rules before billing the included procedure codes.

• Procedure codes in the policy are provided as a reference and may not be all‑inclusive.
• Confirm code-specific prior‑auth requirements in the payer portal or member benefit documents.

Check proprietary test coding

Certain proprietary molecular or infectious‑disease tests are mapped to HCPCS (for example, Abbott Alinity m STI Assay and proprietary resistance assays); verify billing and medical‑policy requirements for these proprietary HCPCS codes before submission.

• When ordering a proprietary test, document the manufacturer/lab and specific assay (e.g., Abbott Alinity™ m STI Assay).
• Confirm that the provider’s billing system maps the proprietary assay to the correct HCPCS code (e.g., 0402U, 0483U, 0484U).

Coding updates — verify payer authorization requirements

After off‑cycle coding or other code changes, verify whether newly added CPT/HCPCS codes require payer notification or prior authorization per local administrative rules.

• Examples of off‑cycle additions include 87494, 0483U, 0484U, 87626; confirm payer systems recognize these codes.
• If a code is new to the policy, validate billing guidance with the payer before claim submission.

Step to culture for treatment non-response

If a patient does not respond to initial gonorrhea therapy, culture testing for N. gonorrhoeae to determine antimicrobial susceptibility MEETS COVERAGE CRITERIA and should be performed to guide treatment.

• Order culture and susceptibility testing when there is clinical or microbiologic evidence of treatment failure.
• Document prior treatment, timing, and clinical response to justify culture for antimicrobial susceptibility.

Step therapy — not applicable in excerpt

No step‑therapy restrictions are described in the excerpt; the policy does not impose prior therapeutic trial requirements for listed STI diagnostic tests.

• Step therapy is not specified for diagnostic testing in this policy excerpt.
• Follow clinical guidelines for test sequencing (e.g., NAAT preferred for CT/NG) rather than a payer step‑therapy mandate.

Supporting clinical documentation recommended

Document the patient's risk group status, presenting symptoms, pregnancy status, HIV status, timing relative to prior diagnosis or treatment, and PrEP or transplant status when ordering STI tests to support medical necessity.

• Include pregnancy status and gestational timing for prenatal testing documentation.
• Record prior infection dates and dates of treatment when ordering tests as tests of cure or follow‑up.

Assay, specimen, and indication documentation

Record the specific assay used, specimen type (e.g., first‑void urine, clinician‑ or patient‑collected vaginal swab, endocervical swab, pharyngeal swab, rectal swab) and the indication (screening vs symptomatic) because product performance varies by specimen and indication.

• Document assay name/manufacturer (e.g., Cepheid Xpert CT/NG, Abbott Alinity m STI) and specimen type in the medical record and lab requisition.
• For extragenital exposure, document the anatomic site to justify extragenital NAAT collection.

Specimen and test documentation for ulcerative disease

For evaluation of genital, anal, or perianal ulcers, include syphilis serology and direct detection (darkfield or lesion NAAT/PCR) when available; for suspected HSV, perform NAAT from lesion specimens and document lesion testing.

• Order both treponemal and nontreponemal serology and lesion NAAT/darkfield if available for ulcerative disease.
• Document lesion site, timing of lesion onset, and specimen type collected for HSV or T. pallidum testing.

For syphilis, document results of both a nontreponemal and a treponemal test

When diagnosing syphilis, document results of both a nontreponemal test (e.g., RPR or VDRL) and a treponemal test (e.g., TP‑PA, EIA/CLIA); for neurologic/ocular/otologic signs, document CSF analysis and CSF‑VDRL.

• If a treponemal test is positive but the nontreponemal test is negative, repeat both tests in one month when early infection is suspected.
• Record quantitative NTT titers (and dilutions) when used for diagnosis or test‑of‑cure monitoring.

Prenatal syphilis testing documentation

For prenatal care in areas with outbreaks or ongoing maternal risk, repeat maternal syphilis serology at 28–32 weeks and at delivery; ensure documentation and do not discharge newborns until maternal syphilis results are known when relevant.

• Document maternal syphilis test dates and results in the prenatal record.
• Ensure timing of repeat testing (28–32 weeks and at delivery) is recorded when indicated by local outbreak or risk status.

LDT validation/documentation

Laboratory‑developed tests (LDTs) used by clinical laboratories must be validated per CLIA requirements; document LDT validation and that the test was performed in a CLIA‑certified high‑complexity lab when applicable.

• If using an LDT for T. pallidum or other organisms, include validation documentation and performance characteristics in the lab record.
• FDA approval status and CLIA validation should be documented for proprietary vs in‑house assays.

Document relevant signs/symptoms for syphilis-related testing

Document clinical signs and symptoms that support syphilis‑related testing, including neurologic, ocular, otologic, or late/tertiary signs, to support medical necessity for advanced testing and CSF analysis when present.

• When ordering CSF‑VDRL or neurosyphilis workup, record specific neurologic or ocular findings prompting the test.
• Include physical exam findings (e.g., cranial nerve dysfunction, vision or hearing changes) in the chart to justify expanded testing.

Denial risk for non-covered test methods

Tests explicitly listed as DO NOT MEET COVERAGE CRITERIA (for example: PCR/NAAT/antigen testing for syphilis; culture/antigen/antibody for chlamydia; rapid EIA for Trichomonas; nucleic acid susceptibility testing for N. gonorrhoeae or macrolide resistance in M. genitalium) may trigger claim denials when billed as covered services.

• Before ordering or billing a modality listed as DNMCC, verify that an alternative covered test is not indicated.
• If ordering a DNMCC test for research or public health reasons, obtain prior authorization or document exceptional circumstances per payer rules.

Specimen-dependent performance

Specimen type and collection method affect test performance; document that an appropriate specimen was collected (e.g., first‑void urine, appropriate rectal swab technique) because improper collection can reduce sensitivity and affect claim validity.

• Record collection method (self‑collected vs clinician‑collected) and time of collection (first‑void urine) in the requisition.
• For rectal specimens, note collection technique and rationale because sensitivity is lower and may require documentation.

Testing method recommendation — use NAATs for CT/NG

Testing for chlamydia and gonorrhea should be performed using NAATs as the preferred method; failure to use recommended NAAT methods may represent inappropriate testing choices.

• Order NAATs for urogenital and indicated extragenital sites (pharyngeal, rectal) per exposure history.
• If a non‑NAAT method is used, document clinical justification and that NAAT was unavailable or inappropriate.

Using only one type of serologic test is insufficient for syphilis diagnosis

Using only a single serologic test (either nontreponemal or treponemal alone) is insufficient to diagnose syphilis and can produce false‑negative or false‑positive interpretations; document both test results per the two‑test algorithm.

• When a treponemal test is positive and NTT is negative, repeat testing in one month if early infection suspected.
• Perform and document quantitative NTT titers when using NTTs for diagnosis or test‑of‑cure.

Government policy precedence

If this policy conflicts with any government coverage policy (LCD/NCD/state Medicaid), the government policy takes precedence and noncompliance with applicable government policy may lead to denials.

• Check Medicare LCD/NCD and state Medicaid rules for beneficiaries before ordering or billing.
• Document adherence to applicable government policy when it differs from this policy to support coverage.

Procedure codes appearing in Medical Policy

Procedure codes listed in Medical Policy documents are provided as a general reference and may not be all‑inclusive; verify coding completeness before submission.

• Use the policy code lists as a guide but confirm with current CPT/HCPCS manuals and payer code lists.
• If a required billing code is missing from the policy, contact the payer’s provider relations for clarification prior to claim submission.

Tests listed as not meeting coverage criteria may be denied

Testing modalities explicitly listed as 'DO NOT MEET COVERAGE CRITERIA' (for example PCR/NAAT/antigen for syphilis; culture, antibody, and antigen testing for chlamydia/LGV; nucleic acid susceptibility testing for N. gonorrhoeae or macrolide resistance in M. genitalium) are triggers for denial when submitted as standalone covered services.

• Avoid ordering or billing DNMCC modalities as covered services unless there is a documented exception or prior authorization.
• If a DNMCC test is required for public health, surveillance, or research, obtain payer confirmation and document the reason.